Department of Medical Genetics, St Mary's Hospital, Manchester Academic Health Sciences Centre, University of Manchester, United Kingdom.
Clin Appl Thromb Hemost. 2011 Jun;17(3):293-6. doi: 10.1177/1076029609356427. Epub 2010 Mar 8.
A 39-year-old Afro-Caribbean man with Crohn disease with recurrent deep vein thromboses and pulmonary emboli was commenced on lifelong warfarin treatment. The patient required high-dose warfarin (>140 mg/wk), which increased further during azathioprine treatment. Cessation of azathioprine resulted in an increase in the international normalized ratio (INR). Mutation analysis identified a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 (VKORC1), consistent with severe warfarin resistance. This report is the first presentation where the patient had a defined hereditary resistance to warfarin, which was aggravated by concomitant azathioprine. It is important for clinicians to be aware of the interaction between warfarin and azathioprine, to monitor clinical response closely, and to manage the doses of both drugs accordingly.
一位 39 岁的非裔加勒比男性患有克罗恩病,反复发作深静脉血栓形成和肺栓塞,开始接受终身华法林治疗。该患者需要高剂量华法林(>140mg/周),在使用硫唑嘌呤治疗期间进一步增加。停用硫唑嘌呤导致国际标准化比值(INR)升高。突变分析发现维生素 K 环氧化物还原酶复合物亚基 1(VKORC1)中的 Val66Met 取代,与严重的华法林抵抗一致。本报告首次介绍了患者对华法林的明确遗传性抵抗,同时合用硫唑嘌呤加重了这种抵抗。临床医生需要注意华法林和硫唑嘌呤之间的相互作用,密切监测临床反应,并相应调整两种药物的剂量。